Literature DB >> 10660321

C-kit mutations in core binding factor leukemias.

A Beghini, P Peterlongo, C B Ripamonti, L Larizza, R Cairoli, E Morra, C Mecucci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10660321

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  72 in total

1.  KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice.

Authors:  Ling Zhao; Jan J Melenhorst; Lemlem Alemu; Martha Kirby; Stacie Anderson; Maggie Kench; Shelley Hoogstraten-Miller; Lauren Brinster; Yasuhiko Kamikubo; D Gary Gilliland; P Paul Liu
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.

Authors:  Heidi J Nick; Hyung-Gyoon Kim; Chia-Wei Chang; Kevin W Harris; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

3.  Redefining transplant in acute leukemia.

Authors:  Rob Sellar; Anthony H Goldstone; Hillard M Lazarus
Journal:  Curr Treat Options Oncol       Date:  2011-12

4.  Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.

Authors:  Matteo Brioschi; John Fischer; Roberto Cairoli; Stefano Rossetti; Laura Pezzetti; Michele Nichelatti; Mauro Turrini; Francesca Corlazzoli; Barbara Scarpati; Enrica Morra; Nicoletta Sacchi; Alessandro Beghini
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

5.  Selective KIT inhibitor KI-328 and HSP90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia.

Authors:  Akane Tsujimura; Hitoshi Kiyoi; Yukimasa Shiotsu; Yuichi Ishikawa; Yumiko Mori; Hiroshi Ishida; Tsutomu Toki; Etsuro Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-05       Impact factor: 2.490

6.  CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

Authors:  Liya Roudaia; Matthew D Cheney; Ekaterina Manuylova; Wei Chen; Michelle Morrow; Sangho Park; Chung-Tsai Lee; Prabhjot Kaur; Owen Williams; John H Bushweller; Nancy A Speck
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  MLL-ENL cooperates with SCF to transform primary avian multipotent cells.

Authors:  Cathleen E Schulte; Marieke von Lindern; Peter Steinlein; Hartmut Beug; Leanne M Wiedemann
Journal:  EMBO J       Date:  2002-08-15       Impact factor: 11.598

8.  Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Authors:  Holly Martin; Raghuveer Singh Mali; Peilin Ma; Anindya Chatterjee; Baskar Ramdas; Emily Sims; Veerendra Munugalavadla; Joydeep Ghosh; Ray R Mattingly; Valeria Visconte; Ramon V Tiu; Cornelis P Vlaar; Suranganie Dharmawardhane; Reuben Kapur
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 9.  Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.

Authors:  Michihiro Kobayashi; Sisi Chen; Rui Gao; Yunpeng Bai; Zhong-Yin Zhang; Yan Liu
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.